Live Internet broadcasts of each of the presentations will be made by visiting the Investor Relations segment of the company’s online page in www.xoma.com.Reproductions of any of the presentations may be held and archived on the site for 90 days after the event.
On a proposal from XOMA Corporation, XOMA has built a significant portfolio of products that are authorized and evolved through other biotech and pharmaceutical companies.The portfolio of systems financed through the company’s partners covers several stages of the drug progression procedure and in areas of healing.Licensing is the result of XOMA’s pioneering efforts in the discovery and progression of healing antibodies.The company’s royalty aggregation business style includes the acquisition of more licenses for third-party-funded systems.For more information, visit www.xoma.com.
Forward-Looking Statements / Explanatory Notes Some of the sections of this press release are forward-looking within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Stock Exchange Act of 1934, adding those relating to perspective. from XOMA’s portfolio of partner systems and licensed technologies that generate significant profits and royalties over time, creating higher shareholder prices and a predicted cash flow. These are based on assumptions that may not turn out to be accurate, and the actual effects may also differ materially from those expected due to certain dangers inherent in the biotech industry, in addition to those related to our product applicants. off-license topic deals are still being developed, and our licensees may want a really large budget to continue progress that might not be available; We do not know if there will be, or will continue to exist, a viable market for the products in which we have an interest or a royalty; If applicants for curative products for which we have a royalty do not obtain regulatory approval, our third party licensees will not be able to market them. Other potential dangers to XOMA’s assembly, those expectations are outlined in more detail in XOMA’s most recent filing on Form 10-K and other SEC filings. Consider those dangers carefully as you contemplate the prospects for XOMA. Any forward-looking statement in this press release represents XOMA’s views only as of the date of this press release and does not deserve to be taken as a representation of its views at any time in the near future. XOMA disclaims any legal responsibility to update any arrangement for the future, unless required by applicable law.
From this press release, all assets in XOMA’s portfolio of milestones and royalties are experimental compounds, efficiency and protection have not been established.There is no guarantee that any of these assets will be available on the market.
Investor Contact: Juliane Snowden Oratorium Group, LLC [email protected]
Media Contact: Kathy VincentKV Consulting